Revenue (Quarterly) Chart

View Revenue (Quarterly) for NTRB.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue (Quarterly) Chart
Start Trial

Historical Revenue (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
July 31, 2026 0.4375M
April 30, 2026 0.4334M
January 31, 2026 0.4007M
October 31, 2025 0.3461M
July 31, 2025 0.6225M
April 30, 2025 0.6674M
January 31, 2025 0.6424M
October 31, 2024 0.6458M
July 31, 2024 0.4428M
April 30, 2024 0.4085M
January 31, 2024 0.5246M
October 31, 2023 0.4278M
July 31, 2023 0.6559M
April 30, 2023 0.4769M
January 31, 2023 0.5275M
October 31, 2022 0.618M
July 31, 2022 0.4561M
April 30, 2022 0.4779M
January 31, 2022 0.4919M
October 31, 2021 0.283M
July 31, 2021 0.2137M
April 30, 2021 0.4335M
Date Value
January 31, 2021 0.3481M
October 31, 2020 0.3918M
July 31, 2020 0.0844M
April 30, 2020 0.1194M
January 31, 2020 0.0196M
October 31, 2019 0.0826M
July 31, 2019 0.0749M
April 30, 2019 0.1936M
January 31, 2019 0.0825M
October 31, 2018 0.1628M
July 31, 2018 0.00
April 30, 2018 0.00
January 31, 2018 0.00
October 31, 2017 0.00
July 31, 2017 0.00
April 30, 2017 0.00
January 31, 2017 0.00
October 31, 2016 0.00
July 31, 2016 0.00
April 30, 2016 0.00
January 31, 2016 0.00

Revenues Definition

Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.

Read full definition.

Revenue (Quarterly) Range, Past 5 Years

View Revenue (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue (Quarterly) Benchmarks

View Revenue (Quarterly) Benchmarks
Start Trial
ANI Pharmaceuticals, Inc. 266.04M
Corcept Therapeutics, Inc. 256.15M
Veru, Inc. 0.00
Johnson & Johnson 25.32B
Eli Lilly & Co. 22.97B